Related Experiment Video
Updated: Aug 3, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Possible effect of thyroid function on anticoagulant response to unfractionated heparin
1Visicu, Inc., 217 East Redwood Street, Suite 1900, Baltimore, MD 21202, USA. obadawi@visicu.com
Abstract:
Many factors are known to influence the unfractionated heparin (UFH) dosage required to achieve therapeutic anticoagulation, including weight, sex, age, tobacco smoking, and diabetes mellitus. However, no interaction between thyroid function and UFH has been documented. An 83-year-old Caucasian woman had active hyperthyroidism that appeared to significantly increase her dosage requirements for UFH. The patient had atrial fibrillation secondary to the hyperthyroidism. She had no known factors that would increase UFH requirements. A UHF dosage of 1400 U/hour was needed to achieve a therapeutic level of anticoagulation (activated partial thromboplastin time 62 sec). After she was treated for hyperthyroidism, her atrial fibrillation resolved and UFH was discontinued. On day 9 of her hospital admission, atrial fibrillation resumed, and the patient's thyroid function began to normalize. Unfractionated heparin was restarted, and this time therapeutic anticoagulation was achieved with only 800 U/hour. This patient's experience suggests a previously undocumented and clinically significant relationship between active hyperthyroidism and altered dosage requirements for UFH. Recognition of this potential interaction may shorten the time required for patients with hyperthyroidism to achieve therapeutic anticoagulation, thereby preventing complications associated with subtherapeutic anticoagulation.
Related Concept Videos
Therapeutic Index
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drug toxicity: Idiosyncratic Reactions
